miRNA Expression and Clinical Data in the Urinary Bladder Cancer and Control Cohort

The data set contains miRNA expression and clinical data in the urinary bladder cancer and control cohort. Reagents, commercial kits, equipment, and testing procedure described in Supplement 1.
The testing material - the spontaneous fraction of urine collected with the VACUTEST Urine Collection system without preservative.
Exosome enrichment prior to miRNA isolation was performed in accordance with the protocol by miRCRURY Exosome Cell/Urine/CSF Kit (Qiagen, Hilden, Germany, Cat. No. / ID: 76743).
miRNeasy Mini Kit (Qiagen, Hilden, Germany, Cat. No. / ID: 17004) was used for miRNA and total RNA isolation from urine exosomes according to the manufacturer's protocol.
MiRCURY LNA RT Kit (Qiagen, USA, Cat.No./ID: 339340) was used for reverse transcription and polyadenylation of miRNA to cDNA.
Predesigned miRCURY LNA miRNA Custom PCR Panel YCA34464 (Qiagen, USA, Cat. No. / ID: 339322) were used for quantification of preselected miRNAs.
RT-qPCR data using the miRNA panel was processed with Applied Biosystems® ViiA™ 7 Real-Time PCR according to manufacturer’s protocol. An automatic threshold and baseline were used for all the miRNAs to record the CT value.
The clinical data were collected retrospectively from Pauls Stradins Clinical University Hospital and Riga East University Hospital patient medical records.